Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Likar, R; Köstenberger, M; Nahler, G.
[Cannabidiol in cancer treatment].
Schmerz. 2020; 34(2):117-122
Doi: 10.1007/s00482-019-00438-9
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Köstenberger Markus
- Likar Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Cannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance. OBJECTIVES: Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients. METHODS: Review of the literature on animal experiments and observations in humans. RESULTS: Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals - administration & dosage
- Anxiety - administration & dosage
- Cannabidiol - administration & dosage
- Cannabinoids - therapeutic use
- Cannabis - administration & dosage
- Dronabinol - administration & dosage
- Humans - administration & dosage
- Neoplasms - drug therapy
- Find related publications in this database (Keywords)
- Cannabidiol (CBD)
- Cannabinoids
- Cancer
- Malignant disease
- Tumors